Abstract

Captopril (Capoten - Squibb) is an orally active inhibitor of angiotensin-converting enzyme;¹ the first of its type of drug to be developed. The manufacturer recommends it for the treatment of patients with severe hypertension resistant to conventional drugs or in those who suffer intolerable side-effects with other hypotensive agents. They also suggest its use in resistant heart failure. A detailed review of captopril has been published recently in the New England Journal of Medicine.²